

Global clinical development pipeline

Updated: 03 Aug 2026

Phase 1				Phase 2	Phase 3	Accepted submissions Major markets (U.S., CN, EU, JP)
Sonrotoclax BLC2i 101/102 B-cell malignancies 108 Dose ramp-up	BG-C0979 ADAM9 ADC 101 Solid tumors	BGB-26808 HPK1i 101 Solid tumors		Sonrotoclax BLC2i 103 AML/MDS 105 R/R MM t(11;14) 203 R/R WM	Zanubrutinib BTKi 306 TN MCL 308 R/R MZL, R/R FL 309 pMN	Sonrotoclax BLC2i 201 R/R MCL (EU)
Tacabrutideg BTK CDAC 101/102 B-cell malignancies 104 B-cell malignancies 107 Chr. spontaneous urticaria	BG-C477 CEA ADC 101 Solid tumors	Xaluritamig³ STEAP1xCD3 BiTE® 20180146 mCRPC		Tacabrutideg BTK CDAC 101 R/R CLL 101 R/R WM 102 R/R CLL	Sonrotoclax BLC2i 301 TN CLL 302 R/R MCL 303 R/R CLL 304 TN CLL (vs. AV)	Zanubrutinib BTKi 114 Tablet formulation (JP) 214 R/R MZL (JP)
BG-C9074¹ B7-H4 ADC 101 Solid tumors	BG-T187 EGFRxMETxMET tsAb 101 Solid tumors	BG-A3004 KLRG1 mAb 101 Immunology and Inflammation		Blinatumomab² CD19 x CD3 BiTE® 20180257 R/R B-ALL SubQ, MRD+	Tacabrutideg BTK CDAC 302 R/R CLL 303 R/R CLL 304 R/R CLL (vs. Pirto)	Tislelizumab PD-1 mAb - ZW25-301 1L HER2+ GEA (U.S., CN) 309 1L NPC (JP)
BGB-21447 BCL2i 101 Solid tumors	BG-C0902 EGFRxMETxMET tsADC 101 Solid tumors	BGB-45035 IRAK4 CDAC 101 Immunology and Inflammation		BGB-B2033 GPC3 x 4-1BB bsAb 101 3L+ HCC	BGB-43395 CDK4i 302 1L HR+/HER2- BC	Zanidatamab⁴ HER2 bsAb ZW25-301 1L HER2+ GEA (CN)
BG-75098 CDK2 CDAC 101 Solid tumors	BGB-58067 MTA Coop. PRMT5i 101 Solid tumors		Tarlatamab² DLL3 x CD3 BiTE® DeLLphi-308 2L+ SCLC SubQ	Tarlatamab² DLL3 x CD3 BiTE® DeLLphi-309 2L SCLC alt dosing	Tarlatamab² DLL3 x CD3 BiTE® - DeLLphi-305 1L ES-SCLC MTx - DeLLphi-312 1L ES-SCLC Ind/MTx - DeLLphi-306 LS-SCLC	
BGB-43395 CDK4i 101 Solid tumors	BON-110³ PD1xVEGFxCTLA4 tsAb 101 Solid tumors					
BGB-B455 CLDN6 x CD3 bsAb 101 Solid tumors	BG-C137 FGFR2b ADC 101 Solid tumors				Zanidatamab⁴ HER2 bsAb 302 1L BTC	
BG-75202 KAT6A/Bi 101 Solid tumors 102 Myeloid malignancies	BGB-B2033 GPC3 x 4-1BB bsAb 101 Solid tumors				Tislelizumab PD-1 mAb 310 1L UBC 316 SubQ	

- Hematology
- Lung
- Breast / Gynecological
- Gastrointestinal
- Other cancers
- Immunology and Inflammation

¹ DualityBio collaboration, ² Amgen collaboration, ³ Huahui Health collaboration, ⁴ Zymeworks/Jazz collaboration
Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details